アブストラクト

Title (1) バンコマイシン
Subtitle 特集 抗菌薬TDM臨床実践ガイドライン2022のポイント
Authors 松元一明
Authors (kana)
Organization 慶應義塾大学薬学部薬効解析学講座
Journal 日本病院薬剤師会雑誌
Volume 58
Number 8
Page 889-892
Year/Month 2022 / 8
Article 報告
Publisher 日本病院薬剤師会
Abstract 「はじめに」抗菌薬は薬物動態学/薬力学 (pharmacokinetics/pharmacodynamics : 以下, PK/PD) に基づいて使用することが推奨されている. PK/PD解析により, バンコマイシン (vancomycin : 以下, VCM) の有効性および安全性と最も相関する指標は, 血中濃度時間曲線下面積 (area under the blood concentration-time curve : 以下, AUC) である. これまでAUCの代替指標としてトラフ値が用いられてきたが, 近年の研究により, トラフ値が代替指標とならないケースや, 解析ソフトを用いてAUCを簡便に算出できるようになったため, 今回のガイドラインでは, より安全にVCMを使用することを目的にAUC評価が推奨された. この点が今回のガイドライン改訂の最大のポイントである.
Practice 薬学
Keywords
  • 全文ダウンロード: 従量制、基本料金制の方共に726円(税込) です。

参考文献

  • 1) MJ Rybak : The pharmacokinetic and pharmacodynamic properties of vancomycin, Clin Infect Dis, 42(Suppl 1), S35-S39(2006).
  • 2) GM Pais, SN Avedissian, JN O'Donnell et al.: Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury, Anti-microb Agents Chemother, 2019 Jun 24, 63. doi:10.1128/AAC.00079-19.
  • 3) SN Avedissian, GM Pais, JN O'Donnell et al.: Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model, J Antimicrob Chemother, 74, 2326-2334(2019).
  • 4) M Tsutsuura, H Moriyama, N Kojima et al.: Target trough concentrations associated with the effectiveness and safety of vancomycin and assessment of the usefulness of AUC-guided or trough-guided monitoring strategy : a systematic review and meta-analysis, BMC Infect Dis[Internet], 2021 Feb 6, 21. doi:10.1186/s12879-021-05858-6.
  • 5) K Yanagihara, A Watanabe, N Aoki et al.: Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012 : General view of the pathogens' antibacterial susceptibility, J Infect Chemother, 23, 587-597(2017).
残りの20件を表示する
  • 6) Y Takesue, S Kusachi, H Mikamo et al.: Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan : Comparison of data from nationwide surveillance studies conducted in 2010 and 2014-2015, J Infect Chemother, 23, 339-348(2017).
  • 7) H Hanaki, L Cui, Y Ikeda-Dantsuji et al.: Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011, J Infect Chemother, 20, 527-534(2014).
  • 8) BT Tsuji, MJ Rybak, KL Lau, G Sakoulas : Evaluation of accessory gene regulator(agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus, Antimicrob Agents Chemother, 51, 1089-1091(2007).
  • 9) C Vidaillac, S Gardete, R Tewhey et al.: Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus, J Infect Dis, 208, 67-74(2013).
  • 10) NB Singh, J Yim, S Jahanbakhsh et al.: Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus, Diagn Microbiol Infect Dis, 91, 363-370(2018).
  • 11) K Matsumoto, Y Takesue, N Ohmagari et al.: Practice guidelines for therapeutic drug monitoring of vancomycin : a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring, J Infect Chemother, 19, 365-380(2013).
  • 12) ZK Ye, YL Chen, K Chen et al.: Therapeutic drug monitoring of vancomycin : a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society, J Antimicrob Chemother, 71, 3020-3025(2016).
  • 13) L Clark, LP Skrupky, R Servais et al.: Examining the Relationship between Vancomycin Area under the Concentration Time Curve and Serum Trough Levels in Adults with Presumed or Documented Staphylococcal Infections, Ther Drug Monit, 41, 483-488(2019).
  • 14) AB Kamel, L Bourguignon, M Marcos et al.: Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients, Ther Drug Monit, 39, 83-87(2017).
  • 15) MP Pai, M Neely, KA Rodvold, TP Lodise : Innovative approaches to optimizing the delivery of vancomycin in individual patients, Adv Drug Deliv Rev, 77, 50-57(2014).
  • 16) MN Neely, G Youn, B Jones et al.: Are vancomycin trough concentrations adequate for optimal dosing?, Anti-microb Agents Chemother, 58, 309-316(2014).
  • 17) K Oda, Y Hashiguchi, T Kimura et al.: Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application, Pharm Res, 38, 637-646(2021).
  • 18) M Yasuhara, T Iga, H Zenda et al.: Population pharmacokinetics of vancomycin in Japanese adult patients, Ther Drug Monit, 20, 139-148(1998).
  • 19) N Hashimoto, T Kimura, Y Hamada et al.: Candidates for area under the concentration-time curve(AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients, J Glob Antimicrob Resist, 27, 12-19(2021).
  • 20) 日本化学療法学会/日本TDM学会, 日本化学療法学会抗菌薬TDMガイドライン作成委員会/日本TDM学会TDMガイドライン策定委員会 : "抗菌薬TDM臨床実践ガイドライン2022", 日本化学療法学会, 東京, 2022.
  • 21) N Shime, T Kosaka, N Fujita : The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia, Eur J Clin Microbiol Infect Dis, 29, 1475-1479(2010).
  • 22) TP Lodise, GL Drusano, E Zasowski et al.: Vancomycin exposure in patients with methicillin-resistant Staphylo-coccus aureus bloodstream infections : how much is enough?, Clin Infect Dis, 59, 666-675(2014).
  • 23) AM Casapao, TP Lodise, SL Davis et al.: Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis, Antimicrob Agents Chemother, 59, 2978-2985(2015).
  • 24) TP Lodise, SL Rosenkranz, M Finnemeyer et al.: The Emperor's New Clothes : Prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant staphylococcus aureus bloodstream infections(PROVIDE), Clin Infect Dis, 70, 1536-1545(2020).
  • 25) KM Gawronski, DA Goff, J Brown et al.: A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureusbacteremia and osteomyelitis, Clin Ther, 35, 772-779(2013).